Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Communications|August 5, 2025
The hidden risks of CRISPR/Cas: structural variations and genome integrityClotilde Aussel, Toni Cathomen, Carla Fuster-García
Human Gene Therapy|July 2, 2026
Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational PerspectivesGhazale Minaiyan, Clotilde Aussel, Sandra Ammann, et al.
Peerj|June 6, 2022
Quality assessment of a serum and xenofree medium for the expansion of human GMP-grade mesenchymal stromal cellsClotilde Aussel, Elodie Busson, Helene Vantomme, et al.
Stem Cell Research & Therapy|August 6, 2021
IL-1β primed mesenchymal stromal cells moderate hemorrhagic shock-induced organ injuriesClotilde Aussel, Nathalie Baudry, Marion Grosbot, et al.
Journal of Translational Medicine|December 24, 2024
IL-1β primed mesenchymal stromal cells moderate hemorrhagic shock-induced vascular permeabilityNathalie Baudry, Aurélie Campeanu, Clotilde Aussel, et al.
Stem Cells and Development|October 31, 2019
Effect of Preconditioned Mesenchymal Stromal Cells on Early Microvascular Disturbance in a Mouse Sepsis ModelNathalie Baudry, Julie Starck, Clotilde Aussel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 19, 2025
Base edited skin equivalents with clinical potential for ex vivo correction of recessive dystrophic epidermolysis bullosaAlex Bassons-Bascuñana, Blanca Duarte, Estela Méndez-Jiménez, et al.
Nature Communications|August 12, 2025
Targeted gene editing and near-universal cDNA insertion of CYBA and CYBB as a treatment for chronic granulomatous diseaseJonas Holst Wolff, Thomas Wisbech Skov, Didde Haslund, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2025
Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosaMarkus Hierl, Johannes Bischof, Bernadette Liemberger, et al.
Nature Communications|April 1, 2025
Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell diseaseSteicy Sobrino, Laure Joseph, Elisa Magrin, et al.
Pageof 2